N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Clinical trial NCT06061809 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06061809
- Sponsor
- ImmunityBio, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-07
- Primary completion
- 2029-12-31
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.